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Abstract
Background: This study explored primary healthcare provider and HIV/contraception expert stakeholder
perspectives on South Africa’s public sector provision of contraceptive implants to women living with HIV. We
investigated the contraceptive service-impact of official advice against provision of implants to women using the
HIV antiretroviral drug, efavirenz, issued by the South African National Department of Health (NDoH) in 2014.
Methods: Qualitative data was collected in Cape Town in 2017 from primary healthcare contraceptive providers in
four clinics that provide implants, as well as from other expert stakeholders selected for expertise in HIV and/or
contraception. In-depth interviews and a group discussion explored South Africa’s implant introduction and implant
provision to women living with HIV. Data was analysed using an inductive thematic analysis approach.
Results: Interviews were conducted with 10 providers and 10 stakeholders. None of the four clinics where the
providers worked currently offered the implant to women living with HIV. Stakeholders confirmed that this was
consistent with patterns of implant provision at primary healthcare facilities across Cape Town. Factors contributing
to providers’ decisions to suspend provision of the implant to women living with HIV included: inadequate initial
and ongoing provider training; interpretation of NDoH communications about implant use with efavirenz; provider
unwillingness to risk harming clients and concerns about professional liability; and other pressures related to
provider capacity.
Conclusions: All South African women, including those living with HIV, should have access to the full range of
contraceptive options for which they are medically eligible. Changing guidance should be initiated and
communicated in consultation with primary-level providers and service beneficiaries. Guidance issued to providers
needs to be clear and fully evidence-informed, and its correct interpretation and implementation facilitated and
monitored. Guidance should be accompanied by provider training, as well as counselling messages and tools to
support providers. Generalized retraining of providers in rights-based, client-centred family planning, and in
particular implant provision for women with HIV, is needed. These recommendations accord with the right of
women living with HIV to access the highest possible standard of sexual and reproductive healthcare, including
informed contraceptive choice and access to the contraceptive implant.
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Background
Women’s informed and voluntary use of effective contra-
ception reduces their risk of negative health and socioeco-
nomic outcomes associated with unintended pregnancy
[1, 2]. Offering all women a range of contraceptive options
is essential to their sexual and reproductive health rights
and heightens their ability to make informed, personal
choices which, in turn, increases contraceptive uptake,
acceptability and effective use [3–5]. For women living
with HIV, improving contraceptive choice and service
quality may have added benefits of enabling pregnancy
planning. This has been shown to be an important
strategy for reducing HIV-associated maternal and child
morbidity and mortality, and for preventing vertical HIV
transmission [6–8].
Efforts to better meet the contraceptive needs of
women in South Africa, including of the 21–23% of re-
productive-aged women estimated to be living with HIV
[9–11], were made in 2012 through a comprehensive re-
vision of the 2001 national contraceptive policy. Devel-
oped by the South African National Department of
Health (NDoH), the National Contraception and Fertility
Planning Policy and Service Delivery Guidelines [12] and
the accompanying National Contraception Clinical
Guidelines [13] were designed to expand contraceptive
method choice and access, and to align South Africa’s
guidance with the World Health Organization’s (WHO)
Medical Eligibility Criteria (MEC) for contraceptive use
[14]. Expanding access to long-acting reversible contra-
ceptives (LARCs) (i.e., intrauterine contraception and
sub-dermal contraceptive implants) was central to these
revisions. LARCs require no action for continued use on
the part of users once in situ and have extended
durations of use. This makes them convenient to use
and highly effective [12, 13, 15]. In this context, the
etonogestrel contraceptive implant was introduced into
South Africa’s public sector contraceptive method mix in
2014 [16, 17].
Implant uptake in South Africa was initially promising
but has declined since introduction in 2014 [16], with
concerns about side effects and inadequate health care
provider training as identified contributors underlying
poor provider and community perceptions of implants
[16, 18, 19]. Further, an NDoH circular to healthcare
providers in late 2014 advised against implant provision
to users of certain enzyme-inducing drugs, including the
HIV antiretroviral drug, efavirenz (a key drug used in
the country’s first-line antiretroviral therapy (ART) regi-
men) [20]. Citing pharmacokinetic [21] and some
clinical data [22] showing that implant hormone levels
are reduced in the presence of efavirenz, potentially re-
ducing contraceptive effectiveness, the circular strongly
advised against implant use and recommended implant
discontinuation among implant users also using efavirenz
[20]. This circular was followed months later by a brief
stating women using these medications may choose to
keep implants if already in situ, provided they were
‘properly counselled about the increased risk of pregnancy
because of drug interactions’ and about ‘the importance of
using additional non-hormonal contraceptive measures’
[23]. However, no supportive training or counselling re-
sources accompanied this advice. The WHO MEC states
in respect to use of the implant with efavirenz that ‘the
advantages of using the method generally outweigh the
theoretical or proven risks’ [24]. The initial circular was
controversial because it did not align with this WHO
MEC guidance. Moreover, the 2014 NDoH recommenda-
tions did not recognize and communicate the importance
of potential users’ needs, rights and preferences when
making contraceptive decisions, which was deliberately
emphasised in the 2012 revisions to national contraceptive
guidance and is an essential aspect of rights-based, client-
centred, high-quality contraceptive care as outlined by the
WHO [5, 12, 13]. Subsequent research published in 2015
showed that despite some level of decreased implant ef-
fectiveness among women using efavirenz-based ART, the
rate of unintended pregnancy remains much lower for
these women than for women not using contraception
[25]. Women using the implant while taking efavirenz-
based ART are also at a lower risk of experiencing
unintended pregnancy than women on efavirenz who use
other methods that require regular adherence for effective
use, such as injectables and pills [25, 26].
While the appropriateness of offering implants to
women living with HIV on efavirenz-based ART has
been explored [27, 28], there has been no assessment of
the impact of official guidance on this topic on implant
provision in South African primary healthcare settings.
The objective of this study is to explore South African
primary healthcare providers’ perceptions, knowledge
and practice concerning implant provision in the context
of HIV and ART. Primary healthcare providers’ perspec-
tives are contextualised by those of policy, academic and
clinical stakeholder experts working in HIV and/or
contraceptive care. This research has relevance for
countries and HIV/contraception programmes provid-
ing the contraceptive implant in settings of high HIV
prevalence.
Methods
Study design, participants and recruitment
This study presents qualitative data collected in semi-
structured, in-depth individual interviews and one group
discussion with public-sector primary healthcare contra-
ceptive providers and other expert stakeholders (special-
ist contraception providers; policy-maker/programme
managers and academics working in HIV and contracep-
tive programming, training, clinical care, and research).
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The primary healthcare providers (hereafter referred
to as providers) interviewed include all of the providers
providing family planning services at four public-sector
primary healthcare clinics. Clinics sampled service a
broad cross-section of communities in the Cape Town
area and are situated in a variety of low-income urban
and peri-urban areas. Women seeking contraceptive
services at these clinics are from diverse South African
and migrant backgrounds and of various reproductive
ages, including adolescents and young adults. All four
clinics provide contraceptive implants on site in addition
to a range of other contraceptive methods (injectables,
oral pills, condoms, and intrauterine contraception).
Three of the clinics offer generalised primary healthcare
services and one specialized in adolescent services.
Three provide HIV diagnosis and treatment; one refers
HIV-positive clients for HIV treatment services after
diagnosis. Expert stakeholders (hereafter referred to as
stakeholders) were purposively selected based on their
roles and knowledge from a list compiled a priori by the
researchers who had knowledge of key stakeholders in
the Cape Town area.
Data collection
Interviews were conducted between May and August
2017. Providers were given an information flyer about
the study and invited to be interviewed with the assist-
ance of clinic managers. Stakeholders were contacted via
email, informed about the study and invited to partici-
pate. Separate interview guides were developed for pro-
viders and stakeholders. Prior to finalisation, the guides
were piloted for flow and clarity with members of the
research team as well as representatives from each of the
two participant groups who were not included in study
sample. Participants in both groups were asked about
their overall perspectives on the implant, its introduction
and its provision in the context of HIV and ART. Pro-
vider interviews focused on knowledge, understandings
and interpretations of official guidance about the im-
plant and efavirenz and its impact on their own practice,
and that of colleagues. Stakeholder interviews focused
on the official guidance development process and the
reception, interpretation, implementation and impact of
the guidance at the primary healthcare level. Suggestions
to improve contraceptive choice, care and service
provision for women living with HIV in primary health-
care settings in South Africa were sought from all
participants.
Interviews were conducted in a private space in Eng-
lish by the author (AB), a young, female, University of
Cape Town Masters of Public Health student with an
English-speaking background. They averaged 45 min
duration. While most providers’ first language was isiX-
hosa or Afrikaans, English is the usual language adopted
in the healthcare workspace in South Africa. All partici-
pants confirmed that they were comfortable with being
interviewed in English by AB and indicated that no
interpretation was required.
The majority of interviews with providers were con-
ducted individually, except for a group interview at one
clinic at the request of the clinic manager. This was due
to time constraints and staff work schedules on the day
of interview. The four provider participants in the group
consented to a group format and the research team de-
cided that accommodating the participants in this regard
would not compromise the quality or interpretability of
the data. All interviews with stakeholders were con-
ducted individually at their places of work.
Provider interviews ceased once data saturation was
reached (i.e., the same themes were coming up repeat-
edly). The stakeholder sample was predetermined by the
key stakeholder list compiled by researchers a priori.
Interviews were audio recorded. Informed consent,
including permission to record interviews, was obtained
from all participants prior to interview. Audio files were
deleted after completion of transcription.
Data management and analysis
Author AB transcribed interviews verbatim and
reviewed them alongside voice memos and field notes.
Initial coding was conducted by AB, using NVivo Soft-
ware. Two senior study team members with extensive
qualitative experience (authors JH and CM) reviewed all
transcripts, codes, and themes with AB, discussed and
resolved differing opinions on coding and interpreta-
tions, and the final codes were agreed by the three study
team members. Inductive thematic analysis was used to
identify themes, and results were organized by the inter-
view guides’ main domains: perceptions of South Africa’s
implant introduction and experiences of provision; im-
pact on practice of the NDoH implant-efavirenz guid-
ance; influence of training, capacity and health systems
issues on interpretation and implementation of implant-
efavirenz guidance; and suggestions for future contra-
ceptive policy-making and service delivery initiatives.
Results
Ten providers, all professional nurses, trained in and
currently providing family planning and contraception
services, and 10 stakeholders were interviewed. Stake-
holders were three government women’s health and HIV
programme managers, two HIV clinical researchers, two
obstetricians/gynaecologists (OB/GYNs), a specialist
contraception provider, a family planning trainer, and a
pharmacologist.
None of the clinics at which providers were working
currently offered the contraceptive implant to women
living with HIV, regardless of whether potential implant
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users were receiving efavirenz-based ART, other ART
regimens, or no ART. At all clinics, implants were being
offered to HIV-negative clients. Stakeholders confirmed
that restrictions on implant provision to women living
with HIV were common in clinics across the greater
Cape Town area.
Perceptions of the implant introduction and experiences
of implant provision
Providers and stakeholders reported enthusiasm sur-
rounding the implant’s introduction in 2014, as a welcome
new method important to expanding contraceptive op-
tions, particularly LAR Coptions, for South African
women. A family planning trainer, with several decades’
experience at an HIV-focused non-governmental organ-
isation, stated, 'when [implants] came here…Wow! Here is
something that is going to save [time], and which does not
need the clients to come to the clinic very often. It was a sa-
viour, in our eyes' (family planning trainer, female).Provi-
ders likewise reported initial optimism about the implant,
with one describing it as 'revolutionary when it came'
(professional nurse, female). However, some stakeholders
lamented the early portrayal of the implant as a wide-
reaching, singular solution to South Africa’s high rates of
unintended pregnancy: 'The method was sold to the public
and to the staff as if this is going to be the solution for all
the family planning woes that we’ve had until now. Which
of course it isn’t' (health manager, female). Stakeholders
involved in the provider training during the initial implant
introduction perceived the implant introduction process as
'rushed', 'target-driven', 'not well-coordinated', and 'a poor
reflection' of the 2012 guidelines’ intentions to expand and
respect women’s informed contraceptive choices: 'The
implant was completely foreign to [providers], so I think
the training on its provision was quite rapid and the
focus was insertion - to train them how to put it in, but
the training on how to counsel women about their
options was lacking' (OB/GYN, female). Another stake-
holder involved in the national implant provider train-
ing programme acknowledged that, ‘whilst everyone
denies it, I think there was very much acascading of ‘see
one, do one, teach one" (specialist contraception pro-
vider, female).
Confirming stakeholders’ perceptions of a rapid decline
in implant uptake after initially high levels, providers re-
ported that, while the implant had been very popular
when it was first introduced, insertions at their clinics had
declined quickly thereafter and continued to do so. Pro-
viders perceived that large numbers of clients requested
their implants be removed soon after insertion. In these
cases, providers reported feeling ill-equipped to manage
women’s concerns about the method in an evidence-in-
formed way, often being unsure of whether particular side
effects reported by clients, such as irregular bleeding,
weight changes, headaches, and hair loss, were likely to be
linked to the implant and/or how to appropriately counsel
on and manage these side effects. Providers also reported
that their clients were concerned about information they
had heard about the implant in their communities, and
that they were ill-equipped to respond to this. Such
information included that the implant may be a ‘chip’ used
for surveillance of women, as well as reported incidents of
gangs violently removing implants from women’s arms.
Provider’s believed that this negative information about
implants had circulated widely in communities from soon
after introduction and deterred women from initiating or
retaining the method. Several stakeholders corroborated
that they had heard reports of this kind of information
from providers and clients.
Impact on provider practice of the NDoH implant-
efavirenz guidance
Providers and stakeholders generally reported that the
late 2014 implant-efavirenz guidance from the NDoH
was received at the same time as the general enthusiasm
about the implant’s introduction was diminishing among
potential users and providers. Providers reported that
during this period, in late 2014, clients were expressing
growing and multidimensional concerns about the
method, removal requests were increasing, and uptake
had started to decline. This lead to general provider ap-
prehension about suggesting or providing the implant to
women seeking contraception.
Providers and stakeholders generally remarked that
the 2014 NDoH circular which stated that “women who
are on [efavirenz] should not use […] implants” [20] and
the subsequent brief which used language related to
“safety” as opposed to “contraceptive effectiveness” to
describe the issue [23] intensified general provider
apprehension about the implant method, and also intro-
duced specific concerns about the safety of its use in
women living with HIV. Most stakeholders believed that
there was an inadequate consultation process prior to
the issuing of the NDoH guidance. They mentioned
several problems with the guidance that they believed
were a result of inadequate consultation: that important
differences between medical safety and contraceptive
effectiveness were not clarified; that there was no men-
tion of relative contraceptive effectiveness of different
contraceptive methods; and that the guidance had not
adequately acknowledged the importance of informed
contraceptive method choice and the role of women’s
varying individual needs, values and preferences when
making decisions about which contraceptive method to
use. Most stakeholders and providers viewed the
guidance as having effectively removed the implant as an
option for women on efavirenz-based ART, which then
was applied at the primary healthcare level to all women
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living with HIV. They described the guidance variously
as ‘pre-emptive’, ‘dogmatic’, ‘rushed’, ‘lacking perspective
[with respect to the fact that absolute contraceptive
effectiveness is only one of several factors a woman
considers when choosing a contraceptive and that later
research has shown that other methods such as inject-
ables and oral pills when used with efavirenz may have
higher rates of contraceptive failure than the implant]’.
The guidance was described by the majority of those
interviewed in both groups to have been worded such
that providers might conclude from it that implants
were ‘not medically safe, so let’s just remove them’ (OB/
GYN, female).
All providers confirmed that they believed implants to
be totally contraindicated in the context of HIV infec-
tion, and that this was the general interpretation and
implementation of the NDoH guidance at their clinics
and elsewhere. This confirmed stakeholders’ general per-
ceptions of restricted provision of the implant to women
living with HIV across Cape Town primary healthcare
clinics. Illustrating this, a health manager believed that
providers in her sub-district were reluctant to offer a
method they perceived might harm clients, with con-
cerns about side effects seen as a deterring factor: ‘No
one is being offered – no HIV-positive woman is being of-
fered [implants]. I think they’re just playing safe’ (health
programme manager, female).
Current levels of knowledge and understanding among
providers as to the NDoH rationale behind the implant-
efavirenz directives ranged from vague notions that the
implant should never be provided to ‘chronic clients
[including those living with HIV]’ (professional nurse,
female); to, ‘I’m not sure which one, exactly, the ARV that
is contraindicated with this [implant] …’ (professional
nurse, female); to, ‘We were told the ART, it lowers the
effectiveness - we were told, but how? I never went through
it, or understood it quite clearly’ (professional nurse, fe-
male); to, ‘They say, it’s contraindicated with the drugs that
they’re using, and that person can still fall pregnant when
they are using the [implant] because it is not stronger than
the three-months injection’ (professional nurse, male).
While some providers were aware of the WHO’s MEC
recommendations on implant use with efavirenz, all were
reluctant to provide implants to women living with HIV
pending clear, updated instructions from the NDoH. Pro-
viders described feeling a sense of personal responsibility
for client safety and personal vulnerability, as well as fears
of legal repercussions. ‘It’s not that I’ll find it difficult to in-
sert, but at the end of the day, I’ll be held accountable.
Anything bad that may happen… Some may lay charges,
you know?’ (professional nurse, male).
Stakeholders were more aware of the evidence sur-
rounding the NDoH’s recommendations and viewed it in
accordance with their own understandings of the risk
and benefit decision-making key to providing implants
in the context of efavirenz. They were also more aware
than providers that the guidance was specific to efavir-
enz-based ART rather than to all ART regimens or all
women living with HIV. Rather than denying the im-
plant as an option altogether for women living with HIV
on efavirenz-based ART regimens, specialist contracep-
tion providers generally endorsed the following approach
with clients: explaining the increased risk of implant
failure with efavirenz, the reasons for this, the relative ef-
fectiveness of other methods, and the importance of dual
contraceptive method use with condoms in addition to
the implant to increase effectiveness, Justifying this, they
cited the WHO’s MEC, the original 2012 guidelines
which emphasize the importance of giving all women
choice (including women living with HIV), and evidence
indicating higher comparative typical-use failure rates of
most other available methods. One specialist contracep-
tion provider had written letters for her clients living
with HIV using implants for them to take along to their
primary healthcare providers, stating they could retain
the method if they chose to, ‘so they can carry it with
them, because they go to the clinic and clinic says, ‘No,
you must have that out!’ (specialist contraception
provider, female).
Influence of training, capacity and health systems issues
on implementation of implant-efavirenz guidance
Some providers and stakeholders observed that public
sector healthcare providers had limited time to provide
comprehensive client counselling and choice of contra-
ceptive methods. This was considered especially true for
LARCs, as well as for the implant in the context of
efavirenz and other enzyme inducing drugs. Hence, the
default position was to not counsel on or offer such
methods. One provider described an integrated service
environment where ‘the family planning sister must do
everything. It’s more like a one stop shop that we’re cur-
rently busy doing. So, there are some services that you
are going to neglect. When you’re there, and I must put
in an [implant], and I know there’s a sick child – I must
still see the sick children. I’m not going to put in the [im-
plant]. I’m going to opt for something else. It won’t be the
client’s choice, it will be the provider’s choice, because of
the clients that must still be seen’ (professional nurse, fe-
male). An OB/GYN was also concerned that providers
were often overburdened by the responsibility to ‘under-
stand every single detail about every single condition that
they’re dealing with’ (OB/GYN, male). He believed it was
‘impossible’ to expect providers to properly convey all
necessary information to clients during single consulta-
tions and still find time to facilitate informed contracep-
tive choice, leading providers to focus on what they
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considered to be the more familiar methods which re-
quire less nuanced counselling.
Some stakeholders corroborated this, noting that,
particularly in areas where there was limited provider
training, they had observed a pattern of simplified rule-
following amongst primary healthcare providers. This
was understood as a way for providers to retain their
ability to make efficient decisions whilst managing
heavy workloads and wide-ranging responsibilities: ‘So,
a lot of the clinicians are doing things that they aren’t
necessarily fully trained and equipped for, particularly
the nurse clinicians, and so, they adopt one rule, and
that’s just the way it happens’ (pharmacologist, female).
In the specific case of the implant-efavirenz guidance, ‘I
do think it’s probably easier just to take out the implant
– you just learn the rule and then you follow it’ (HIV
clinician, female).
Notably, some stakeholders believed that inadequate
training on implant provision and counselling (and
subsequent confusion about implant-efavirenz guid-
ance) affected both doctors and nurses in the public
healthcare sector. ‘There was an assumption that
doctors don’t need [implant] training’ (health manager,
female) and, when it came to incorrect insertions,
‘doctors are worse than nurses’ (specialist contracep-
tion provider, female). HIV clinicians were believed to
be more likely to misinterpret the NDoH advice ‘be-
cause a lot of the people who get referred to the fam-
ily planning clinic to take the implant out come from
the HIV clinics’ (OB/GYN, female).
Suggestions for future contraceptive policy-making and
service delivery initiatives
In light of their experiences around implant introduction
and guidance on implant use for women living with HIV,
participants were asked to suggest recommendations for
improving contraceptive choice and services for women
living with HIV in South Africa. Themes emerged related
to: multi-stakeholder consultation when developing guid-
ance; ensuring that contraceptive care is focussed on qual-
ity of counselling and services, which build client-provider
trust, as opposed to numerical targets; and the NDoH
undertaking efforts to improve the reputation of the im-
plant specifically.
At the guidance and policy-making level, stakeholders
emphasized that, when issuing guidance to providers,
NDoH needed to take more time to consult with stake-
holder groups, particularly in circumstances where avail-
able evidence indicates no immediate physical danger
associated with an intervention or service. One health
manager proposed a system of policy ‘panel-beating’.
She explained that policy-makers ‘would improve a lot if
they had things read and interpreted by somebody else.
Sometimes, I get something, and I see it one way, and
then somebody else reads it another way… So, I
frequently call on the secretary, the cleaner, the clerk,
and say, ‘Okay, read this for me. What did you under-
stand?’ (health manager, female). Several stakeholders
stated that significant gaps in primary healthcare pro-
vider knowledge about contraception generally, and the
implant specifically, necessitated widespread retraining.
This was due to the widespread non-provision of im-
plants to all women living with HIV based on unfounded
safety concerns, and regardless of ART regimen. It was
viewed as urgent and timely given the anticipated
upcoming changes in the first-line ART regimen in
South Africa to a dolutegravir-based regimen (an ART
considered highly unlikely to decrease the effectiveness
of implants).
Provider and stakeholders suggested that when new
contraceptive methods are introduced, implementation
should focus more on ensuring that providers are
equipped to facilitate client-centred, rights-based, in-
formed contraceptive choice, rather than placing pres-
sure on clinics to meet numerical targets for method
coverage. Participants in both groups expressed frustra-
tion that ‘pushing for numbers’ (professional nurse,
female) in the case of the implant rollout had compro-
mised client method choice. Related to this, emphasis
in training is needed on building provider-client trust
in contraceptive care and facilitating choice, especially
in offering long-acting options such as the implant. As
one provider explained: ‘We [providers] have this way
of, you know, subtly forcing them to take something
and, ultimately, they walk out and they’re angry with
you as a nurse, as a facility. They’re angry because
you’ve given them something that they didn’t want, and
a three-year device is… It’s a three-year device. So,
irrespective of if they have HIV or they don’t have HIV,
I think if the client has the knowledge and consent – we
need to treat clients as if they were adults’ (professional
nurse, female).
Providers and stakeholders identified a need for the
NDoH to actively address the implant’s broader negative
reputation and misinformation about the implant
amongst providers, women and communities. With re-
gard to the implant-efavirenz directives in particular,
providers stated that they need clarification about its
safety and effectiveness in women living with HIV, and
the rights of women living with HIV to choose the
method. A health manager suggested engaging HIV
activist groups, who ‘play a very important role in
whether a method or system, or drug, or whatever, is go-
ing to be adopted or not. They are very strong activists,
and most of them were scared that they had an [im-
plant] inserted and they were on ARVs. What do you
think they are going to tell the rest of the community?’
(health manager, female).
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Discussion
This study offers the first direct insight into the primary
healthcare level impacts of the South African NDoH’s
guidance on provision of implants to women living with
HIV on efavirenz-based ART regimens. Discussions with
providers revealed that, at all four clinics visited, im-
plants were not currently offered to women living with
HIV. This corresponded with stakeholders’ wider im-
pressions of how the directives have been interpreted
and implemented in primary healthcare settings across
Cape Town. Based on this guidance, providers and
clinics were effectively denying women living with HIV
access to the contraceptive implant.
Our data suggests that several composite factors may
have led to primary healthcare providers implementing
the implant-efavirenz guidance in this very restrictive
way. Stakeholders recalled that the initial implant pro-
vider training programme and rollout in 2014 had been
rushed and poorly coordinated, and felt providers were
not appropriately equipped to counsel women about the
new method in general and less so about more nuanced
and more individualised issues related to implant use
among women living with HIV. Stakeholder and pro-
vider perceptions on the South African implant intro-
duction and early client and provider concerns about the
method that emerged in our study are supported by
other South African research on this topic [16, 18, 29].
By the time the implant-efavirenz guidance was issued,
providers had thus already developed scepticism about
the suitability of the method for their clients in general.
The directives’ wording was perceived by participants to
imply the possibility of harm to a woman’s health associ-
ated with the implant’s interaction with efavirenz, rather
than solely reduced contraceptive effectiveness. Several
participants expressed doubt that many providers, under
pressure to provide integrated services in busy public
sector clinical environments, could have realistically
achieved a nuanced understanding of the directives,
given that these updates were just two among many they
were expected to interpret and implement. Providers
tended to adopt the ‘safe and simple’ rule that implants
were contraindicated with HIV infection, regardless of
ART regimen.
Lipsky’s ‘street-level bureaucracy’ theory suggests that
professional discretion used by civil servants who inter-
act directly with members of the public often fundamen-
tally shapes the way policies associated with public
services are implemented [30]. In the presence of struc-
tural pressures such as heavy workloads, time con-
straints, resource limitations, and training deficiencies,
the capacity of individuals working on the ground to
interpret and implement incoming policies and updates
may be compromised [31]. This predicament tends to
result in the street-level bureaucrat, in this case the
primary-level healthcare provider, implementing infor-
mal, often simplified versions of policies as a ‘coping
strategy’. Such coping behaviour may have been particu-
larly pronounced in the case of providers implementing
the implant-efavirenz directives in this study, where it
was perceived that a ‘judgement call’ to offer or provide
the implant to a woman living with HIV may have risked
harm to a client, or resulted in legal ramifications for
the provider.
This study has implications for implant-efavirenz
directive implementation by primary providers else-
where in South Africa. If representative of how the
implant-efavirenz directives have been implemented
by primary providers elsewhere, the findings of this
study are concerning. They suggest that South African
women living with HIV are potentially being denied
the option to use a safe, convenient and effective
contraceptive method. This is a contravention of
women’s sexual and reproductive health rights [32–
34] and contradicts the intentions of the revisions
made to the South African contraception guidelines
in 2012, which sought to expand contraceptive choice
for all women, including women living with HIV [3,
12, 13]. It additionally contradicts WHO MEC guid-
ance on implant provision in the context of efavirenz-
based ART [14]. With impending changes to South
Africa’s first-line ART regimen (in the near future,
efavirenz will be replaced by dolutegravir [35, 36],
which is a differently classed drug to efavirenz and
one that is unlikely to cause similar drug-drug inter-
actions with the contraceptive implant), it is import-
ant that the South African policy environment
reconsiders the available evidence, that guidance is
updated and clearly communicated, and that providers
are retrained. Providers need support through training
and tools to better understand and accurately deliver
the important counselling message of reduced implant
effectiveness with efavirenz, while still allowing efavir-
enz-using clients to choose the implant. They also
need training to understand and communicate that as
dolutegravir, which is unlikely to reduce implant ef-
fectiveness, replaces efavirenz, and counselling mes-
sages on this topic will need to change.
Participants’ suggestions for improving the quality of
contraceptive care to women were similar to existing
literature [3, 16, 18]. In policy-making, sufficient time
should be taken to conduct an appraisal of evidence and
stakeholder perspectives to minimize unintended conse-
quences and misinterpretation of recommendations.
Provider retraining on implant provision and counselling
is needed, as well as on choice-based, client-centred
contraceptive care. Counselling could be made more
time-efficient in busy clinical settings with standardized
messages and decision-making tools and user-friendly
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materials for clients to absorb in clinic waiting rooms
and at home. Targeted provider and community engage-
ment to improve perceptions of and dispel misinforma-
tion about the implant generally is needed.
Limitations
This qualitative study of 20 participants is limited by
being confined to the Cape Town Metropolitan Area. It
may therefore not be generalizable. However, the in-
sights gained are likely to have transferability to other
public sector primary healthcare settings in South Africa.
The participating clinics serve a relatively broad cross-
section of communities using public sector primary
healthcare services. The women utilizing contraceptive
services at the clinics were from diverse South African
and migrant backgrounds and of various reproductive
ages, including adolescents and young adults. The clinics
were also situated in a variety of low-income urban and
peri-urban areas. In addition, stakeholders were chosen
to represent a diversity of expertise and experience
pertaining to HIV and/or contraceptive care and service
delivery. Interviews being conducted in English may
have resulted in some limitations; however, all partici-
pants indicated comfort with English for interviews and
this is the usual language used in the healthcare work-
space in South Africa. Power imbalances between the
interviewer and participants may have existed; however,
in qualitative research, the researcher is deeply cognisant
of power relations and triangulation of data was used,
with the aim of minimizing the impact of power imbal-
ances on data quality.
Conclusions
The findings of this study suggest that the South African
NDoH’s 2014 guidance on contraceptive implant use
among women using efavirenz may have had unintended
consequences at the primary care level. It may have
effectively removed the safe, effective and convenient
implant as a contraceptive option for all women living
with HIV, thus, denying them informed contraceptive
choice and infringing on their sexual and reproductive
health rights. The appropriateness of the recommenda-
tion against implant use in the context of efavirenz-
based ART is still under debate. The upcoming move to
dolutegravir-based ART in South Africa and elsewhere
underscores the urgent need for further investigation
and evidence-based action by international bodies,
countries and HIV and family planning programmes. A
challenge for future research and policy development in
this area will be creating and implementing robust and
effective training and re-training programmes and coun-
selling tools that enable and entrench the principal of
individualised, informed contraceptive choice for clients.
This is particularly important for providers working in
busy multipurpose integrated health service environ-
ments. Service beneficiaries and stakeholders at all levels
should be consulted throughout policy development, de-
cision-making and introduction phases, so that guidance
stands the best chance of being correctly interpreted and
well-implemented. The study additionally provides some
insights and lessons for introduction of other new public
health products.
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